BIOADAPTIVES INC (BDPT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 19, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BDPT SEC filings page.
BIOADAPTIVES INC (BDPT) reported $18K in revenue for fiscal year 2025, up 44.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovered to $18.3M and gross margin reached 68.4% , yet operating losses widened, revealing weak conversion into company-wide earnings.
Gross margin expansion from31.8% in FY2024 to68.4% in FY2025 did not translate into better operating performance. Operating losses widened from$602K to$1.0M , indicating that costs below gross profit—or other operating charges—overwhelmed the improved product-level economics.
Cash conversion remains negative: operating cash flow was
The balance sheet is structurally dependent on outside financing: FY2025 liabilities of
Financial Health Signals
BIOADAPTIVES INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BIOADAPTIVES INC scores -92.88, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($394K) relative to total liabilities ($2.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BIOADAPTIVES INC passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
BIOADAPTIVES INC reported an operating loss of $1.0M against $71K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BIOADAPTIVES INC generated $5K in revenue in Q2 2026. This represents an increase of 55.0% from the same quarter a year earlier. Against the prior quarter it is down 9.5%.
BIOADAPTIVES INC's EBITDA was -$196K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 44.6% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.
BIOADAPTIVES INC reported $150K in net income in Q2 2026. This represents an increase of 195.0% from the same quarter a year earlier. Against the prior quarter it is up 235.1%.
Cash & Balance Sheet
BIOADAPTIVES INC held $29K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
BIOADAPTIVES INC's gross margin was 85.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 52.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.4 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
BDPT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K+55.0% | $6K | N/A | $5K | $3K+376.9% | $0-100.0% | N/A | $0-100.0% |
| Cost of Revenue | $748-65.3% | $1K | N/A | $781 | $2K+776.4% | $0-100.0% | N/A | $0-100.0% |
| Gross Profit | $4K+298.9% | $4K | N/A | $4K | $1K+147.8% | $0-100.0% | N/A | $0-100.0% |
| SG&A Expenses | $178K-10.2% | $181K+26.3% | N/A | $251K+521.3% | $198K+4186.2% | $143K+352.7% | N/A | $40K+19.8% |
| Operating Income | -$197K+29.4% | -$198K+20.4% | N/A | -$266K-117.9% | -$279K | -$249K-400.0% | N/A | -$122K-32.2% |
| EBITDA | -$196K+44.6% | -$197K-13.0% | N/A | -$264K-116.7% | -$353K | -$174K | N/A | -$122K |
| Interest Expense | $115K+1092.2% | $88K+809.7% | N/A | $14K+46.0% | $10K-46.3% | $10K-82.3% | N/A | $10K-53.0% |
| Net Income | $150K+195.0% | -$111K+43.7% | N/A | -$380K-908.0% | -$158K | -$197K | N/A | -$38K-188.3% |
| EPS (Basic) | $0.01+150.0% | N/A | N/A | N/A | -$0.02 | N/A | -$0.11+8.3% | $0.00 |
| EPS (Diluted) | $0.00 | -$0.01+50.0% | -$0.07-75.0% | -$0.04 | -$0.02-133.3% | -$0.02 | -$0.04 | $0.00 |
| Diluted Shares (Avg) | 281M | 12M+32.7% | N/A | 10M | 10M+219.3% | 9M | N/A | 8M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
BDPT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $79K-71.1% | $136K+23.1% | $226K-13.7% | $124K+168.1% | $273K+3019.8% | $110K+88.3% | $262K+151.8% | $46K-85.9% |
| Current Assets | $68K-73.5% | $123K+11.8% | $212K-19.1% | $109K+134.6% | $256K+2825.2% | $110K+171.6% | $262K+195.7% | $46K-71.5% |
| Cash & Equivalents | $29K-86.1% | $74K+86.0% | $215K-17.8% | $59K+35.0% | $211K+89509.4% | $40K+101.9% | $262K+195.7% | $44K-71.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% |
| Inventory | $36K-8.9% | $43K+5.9% | $45K+133.9% | $44K | $40K+559.6% | $41K+118.5% | $19K+25.1% | $0-100.0% |
| Accounts Receivable | N/A | N/A | N/A | $59 | $59 | N/A | $0 | N/A |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.8M+31.0% | $2.3M+35.1% | $2.4M+36.5% | $1.6M-14.2% | $1.4M-25.0% | $1.7M-9.4% | $1.7M-1.4% | $1.9M+25.5% |
| Current Liabilities | $1.8M+31.0% | $2.3M+35.1% | $2.4M+36.5% | $1.6M-14.2% | $1.4M-27.1% | $1.7M-9.4% | $1.7M-1.4% | $1.9M+25.5% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0+100.0% | $0 | $0 | $0 |
| Total Equity | -$1.8M-55.6% | -$2.1M-36.0% | -$2.1M-45.5% | -$1.5M+18.8% | -$1.1M+39.2% | -$1.6M+12.6% | -$1.5M+11.1% | -$1.8M-57.6% |
| Retained Earnings | -$10.7M-12.2% | -$10.8M-15.7% | -$10.7M-17.0% | -$9.9M-12.6% | -$9.5M-8.7% | -$9.4M-9.2% | -$9.2M-10.9% | -$8.8M-10.0% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BDPT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$44K+60.0% | -$85K+13.3% | -$156K-55.0% | -$151K-168.6% | -$111K | -$98K-137.7% | -$101K-10.1% | -$56K-0.3% |
| Depreciation & Amortization | $2K+102.0% | $2K-98.0% | $2K | $2K | -$74K | $75K | $0 | $0 |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | $29K | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | $0 | $0 | N/A | N/A | $0 | $0 |
| Free Cash Flow | N/A | N/A | -$156K-55.0% | -$151K-168.6% | N/A | N/A | -$101K | -$56K |
| Investing Cash Flow | N/A | N/A | $0 | $0 | N/A | N/A | $0 | $0 |
| Financing Cash Flow | N/A | N/A | $255K+31.4% | $0-100.0% | N/A | N/A | $194K | $100K-40.5% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BDPT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.0%+52.0pp | 74.6% | N/A | 83.1% | 33.0%-30.5pp | N/A | N/A | N/A |
| Operating Margin | -3953.0% | -3594.8% | N/A | -5735.9% | -8674.1% | N/A | N/A | N/A |
| Net Margin | 3009.0% | -2014.6% | N/A | -8193.0% | -4905.7% | N/A | N/A | N/A |
| Return on Assets | 190.6%+248.5pp | -81.7%+96.8pp | N/A | -305.2%-224.0pp | -58.0% | -178.5% | N/A | -81.2%-77.2pp |
| Current Ratio | 0.04-0.1x | 0.050.0x | 0.09-0.1x | 0.070.0x | 0.18+0.2x | 0.070.0x | 0.15+0.1x | 0.03-0.1x |
| Asset Turnover | 0.06+0.1x | 0.040.0x | N/A | 0.040.0x | 0.01-0.1x | 0.00-0.2x | N/A | 0.000.0x |
| FCF Margin | N/A | N/A | N/A | -3266.6% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$2.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.09), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BIOADAPTIVES INC BDPT | FY2025 | $18K | N/A | N/A | $394K | — |
| NETBRANDS CORP NBND | FY2025 | $18K | N/A | N/A | $47K | — |
| BLUE STAR FOODS CORP BSFC | FY2025 | $2.9M | -$3.6M | N/A | $992K | — |
| RIGHT ON BRANDS INC RTON | FY2023 | $1.1M | $9K | 0.8% | $665K | — |
Where BIOADAPTIVES INC Ranks
Frequently Asked Questions
What is BIOADAPTIVES INC's annual revenue?
BIOADAPTIVES INC (BDPT) reported $18K in total revenue for fiscal year 2025. This represents a 44.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BIOADAPTIVES INC's revenue growing?
BIOADAPTIVES INC (BDPT) revenue grew by 44.3% year-over-year, from $13K to $18K in fiscal year 2025.
What is BIOADAPTIVES INC's EBITDA?
BIOADAPTIVES INC (BDPT) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BIOADAPTIVES INC's gross margin?
BIOADAPTIVES INC (BDPT) had a gross margin of 68.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BIOADAPTIVES INC's free cash flow?
BIOADAPTIVES INC (BDPT) recorded an outflow of $534K in free cash flow during fiscal year 2025. This represents a -114.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BIOADAPTIVES INC's operating cash flow?
BIOADAPTIVES INC (BDPT) recorded an outflow of $516K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BIOADAPTIVES INC's total assets?
BIOADAPTIVES INC (BDPT) had $226K in total assets as of fiscal year 2025, including both current and long-term assets.
What are BIOADAPTIVES INC's capital expenditures?
BIOADAPTIVES INC (BDPT) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is BIOADAPTIVES INC's current ratio?
BIOADAPTIVES INC (BDPT) had a current ratio of 0.09 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is BIOADAPTIVES INC's P/E ratio?
BIOADAPTIVES INC (BDPT) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $394K as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BIOADAPTIVES INC's price-to-sales ratio?
BIOADAPTIVES INC (BDPT) trades at 21.5x sales, its market capitalization divided by revenue of $18K revenue, FY2025. The market capitalization is $394K as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does BIOADAPTIVES INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BIOADAPTIVES INC (BDPT) held $215K in cash, cash equivalents and investments, and reported an operating cash outflow of $516K over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is BIOADAPTIVES INC's debt-to-equity ratio negative or not reported?
BIOADAPTIVES INC (BDPT) has negative shareholder equity of -$2.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is BIOADAPTIVES INC's Altman Z-Score?
BIOADAPTIVES INC (BDPT) has an Altman Z-Score of -92.88, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BIOADAPTIVES INC's Piotroski F-Score?
BIOADAPTIVES INC (BDPT) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Can BIOADAPTIVES INC cover its interest payments?
BIOADAPTIVES INC (BDPT) reported an operating loss of $1.0M against $71K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.